FDA Approved: INCRUSE ELLIPTA — Supplemental Application (GlaxoSmithKline LLC)

View source ↗

Summary

The FDA approved a supplemental application for INCRUSE ELLIPTA (umeclidinium) submitted by GlaxoSmithKline LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Incruse Ellipta (umeclidinium bromide)

Snippet

SUPPL AP for INCRUSE ELLIPTA (UMECLIDINIUM)